MCP
BBC icon

Militia Capital Partners’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Militia Capital Partners’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.21M Sell
31,263
-22,330
-42% -$758K 0.46% 72
2025
Q3 		$1.46M Buy
53,593
+10,400
+24% +$237K 0.68% 44
2025
Q2 		$834K Buy
+43,193
New +$785K 0.39% 71

Other funds holding BBC

KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MML Investors Services
MML Investors Services Springfield, Massachusetts $49B AUM 25.55% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Militia Capital Partners's BBC Position: Q4 2025 in Review

Militia Capital Partners reduced its Virtus Biotech Clinical Trials ETF (BBC) stake by 42% in Q4 2025, selling an estimated $758K and leaving 31,263 shares worth $1.21M. The position accounts for 0.46% of the portfolio, ranked #72.

Militia Capital Partners first reported a position in BBC in Q2 2025 and has held it in 3 quarters since. The position peaked at $1.46M in Q3 2025. 19 funds tracked by Wall St. Rank hold BBC as of Q4 2025.

  • Militia Capital Partners held 31,263 shares of Virtus Biotech Clinical Trials ETF worth $1.21M as of Q4 2025.
  • Militia Capital Partners sold 22,330 Virtus Biotech Clinical Trials ETF shares in Q4 2025, an estimated $758K.
  • Virtus Biotech Clinical Trials ETF made up 0.46% of Militia Capital Partners's portfolio in Q4 2025, its #72 holding.
  • Militia Capital Partners first reported a position in Virtus Biotech Clinical Trials ETF in Q2 2025 and has held it in 3 quarters since.
  • Militia Capital Partners's Virtus Biotech Clinical Trials ETF position peaked at $1.46M in Q3 2025.
  • 19 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q4 2025.

Based on Militia Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.